Skrindo Ingebjørg, Lupinek Christian, Valenta Rudolf, Hovland Vegard, Pahr Sandra, Baar Alexandra, Carlsen Kai-Håkon, Mowinckel Petter, Wickman Magnus, Melen Erik, Bousquet Jean, Anto Josep M, Lødrup Carlsen Karin C
Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Pathophysiology and Allergy Research, Centre of Pathophysiology, Infectology and Immunology, Medical University of Vienna, Vienna, Austria.
Pediatr Allergy Immunol. 2015 May;26(3):239-246. doi: 10.1111/pai.12366.
Allergic sensitization is frequently present in asthma and rhinitis, but the role of specific immunoglobulin E (s-IgE) is not always clear. Multiple s-IgE analyses may provide insight into this relationship, thus a microarray chip was developed within the EU-funded MeDALL project. The main objective was to evaluate the performance of the MeDALL-chip compared to ImmunoCAP and skin prick test (SPT) in detecting allergic sensitization in children and secondarily to investigate the association to asthma and allergic rhinitis.
From the 'Environment and Childhood Asthma Study', 265 children were investigated at 10 and 16 yr of age with clinical examination, interview, SPT, ImmunoCAP, and the MeDALL-chip including 152 allergen components in the analysis.
Allergic sensitization at 10 yr was more frequently detected using the MeDALL-chip (38.1%) compared to the ImmunoCAP (32.8%) (p = 0.034) and SPT (25.5%) (p < 0.001), but no significant difference was seen at 16 yr (MeDALL-chip 49.8%, ImmunoCAP 48.6%, SPT 45.8%). The MeDALL-chip did not differ significantly from the ImmunoCAP or SPT in terms of detecting allergic sensitization in subjects with rhinitis or asthma at 10 or 16 yr.
The prevalence of allergic sensitization increased by all three diagnostic tests from 10 to 16 yr was similar by SPT and ImmunoCAP and significantly higher with the MeDALL-chip at 10 yr. All three tests were comparable for identification of allergic sensitization among children with current rhinitis or asthma.
变应性致敏在哮喘和鼻炎中经常存在,但特异性免疫球蛋白E(s-IgE)的作用并不总是明确的。多次s-IgE分析可能有助于深入了解这种关系,因此在欧盟资助的MeDALL项目中开发了一种微阵列芯片。主要目的是评估MeDALL芯片与免疫捕获法(ImmunoCAP)和皮肤点刺试验(SPT)相比,在检测儿童变应性致敏方面的性能,其次是研究其与哮喘和变应性鼻炎的关联。
从“环境与儿童哮喘研究”中选取265名儿童,在10岁和16岁时进行临床检查、访谈、SPT、ImmunoCAP检测以及使用包含152种变应原成分的MeDALL芯片进行分析。
与ImmunoCAP(32.8%)(p = 0.034)和SPT(25.5%)(p < 0.001)相比,使用MeDALL芯片在10岁时检测到的变应性致敏更为频繁(38.1%),但在16岁时未观察到显著差异(MeDALL芯片49.8%,ImmunoCAP 48.6%,SPT 45.8%)。在10岁或16岁患有鼻炎或哮喘的受试者中,MeDALL芯片在检测变应性致敏方面与ImmunoCAP或SPT相比无显著差异。
从10岁到16岁,所有三种诊断测试检测到的变应性致敏患病率均有所增加,SPT和ImmunoCAP检测结果相似,而MeDALL芯片在10岁时显著更高。在识别当前患有鼻炎或哮喘的儿童的变应性致敏方面,所有三种测试具有可比性。